Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Seelos Therapeutics, Inc. SEEL
$0.88
+$0.01 (0.97%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
107181499.00000000
-
week52high
1.52
-
week52low
0.48
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.94893400
-
EPS
-0.75000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 апр 2023 г. в 10:59
Описание компании
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 14 мар 2022 г. |
| Roth Capital | Buy | Neutral | 27 сент 2021 г. |
| Roth Capital | Neutral | Neutral | 10 авг 2021 г. |
| Guggenheim | Buy | 01 июл 2021 г. | |
| Cantor Fitzgerald | Overweight | 01 июн 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Lian Brian | A | 50000 | 50000 | 05 янв 2023 г. |
| DALESANDRO MARGARET | A | 50000 | 50000 | 05 янв 2023 г. |
| O'Connor Daniel J. | A | 50000 | 50000 | 05 янв 2023 г. |
| Pascoe Richard W | A | 50000 | 50000 | 05 янв 2023 г. |
| O'Connor Daniel J. | A | 16000 | 16000 | 01 июн 2022 г. |
| DALESANDRO MARGARET | A | 35000 | 35000 | 26 мая 2022 г. |
| Mehra Raj | A | 3281546 | 66667 | 31 мар 2022 г. |
| Golembiewski Michael Joseph | A | 78487 | 12500 | 28 февр 2022 г. |
| Golembiewski Michael Joseph | A | 500000 | 500000 | 10 янв 2022 г. |
| Mehra Raj | A | 1300000 | 1300000 | 10 янв 2022 г. |
Новостная лента
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
PRNewsWire
10 февр 2023 г. в 08:00
- Seelos recently released in vivo gene therapy data of SLS-004 utilizing CRISPR-dCas9 in Parkinson's disease demonstrating downregulation of alpha synuclein and recovery of tyrosine hydroxylase-positive (TH+) dopaminergic neurons. NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit in San Francisco, CA, February 21-23, 2023.
Scrutinizing Psychedelic Stocks
Seeking Alpha
08 янв 2023 г. в 11:30
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
PRNewsWire
08 дек 2022 г. в 08:00
NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15 th from 1pm to 3pm ET. Registration is available at https://lifescievents.com/event/seelos-therapeutics-kol-event/ , and https://seelostherapeutics.com/registration-for-12-15-rd-update-webcast/.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Zacks Investment Research
06 дек 2022 г. в 21:49
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
InvestorPlace
28 окт 2022 г. в 14:49
Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.